Filing Flows › NRX Pharmaceuticals (NRXP) › Q2 2026 › vs Q1 2026
NRX Pharmaceuticals (NRXP) Q2 2026 vs Q1 2026 (quarter over quarter)
NRX Pharmaceuticals's revenue rose $33K (+3%) from $1.1M in Q1 2026 to $1.1M in Q2 2026. The biggest changes: Therapy +$111K (+15%); Procedures −$78K (-25%).
NRX Pharmaceuticals, Q2 2026: revenue $1.1M, operating margin -590.8%, net loss $16.5M, operating cash flow −$8.9M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Therapy | $871K | $760K | $111K | +15% |
| Procedures | $230K | $308K | −$78K | -25% |
| Revenue | $1.1M | $1.1M | $33K | +3% |
| Net loss | $16.5M | $1.4M | $15.1M | 12× |
| Costs & expenses | $17.6M | $5.8M | $11.8M | +203% |
| Operating costs | $7.6M | $5.8M | $1.8M | +31% |
| Interest & other, net | $10.0M | −$3.3M | $13.3M | — |
| Cost of revenue | $675K | $631K | $44K | +7% |
| Research & development | $2.1M | $1.3M | $807K | +62% |
| SG&A | $4.7M | $3.8M | $932K | +24% |
| Other operating costs | $70K | $57K | $13K | +23% |
| Operating cash sources | $16.5M | $1.4M | $15.1M | 12× |
| Depreciation & amortization | $71K | $63K | $8K | +13% |
| Share-based compensation | $139K | $151K | −$12K | -8% |
| Working capital & other | $7.4M | −$3.1M | $10.5M | — |
| Cash used in operations | $8.9M | $4.3M | $4.6M | +107% |
| Net loss absorbed | $16.5M | $1.4M | $15.1M | 12× |
Questions
How much did NRX Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
NRX Pharmaceuticals's revenue rose $33K (+3%) from $1.1M in Q1 2026 to $1.1M in Q2 2026.
What drove NRX Pharmaceuticals's revenue change in Q2 2026?
Therapy +$111K (+15%); Procedures −$78K (-25%).